Scholarlink

Purpose <p>Advancements in prostate cancer diagnostics have changed the diagnostic pathway from traditional ultrasound-guided systematic transrectal biopsies to pre-biopsy prostate multiparametric MRI and targeted transperineal biopsies. This study aims to determine changes in prostate cancer detection rates, clinical outcomes, and treatment before (2018) and after (2023) implementing the new diagnostic pathway.</p> Methods <p>This retrospective study comprises two cohorts from two Danish hospitals—one from 2018 (<i>n</i> = 266) and one from 2023 (<i>n</i> = 304). In each cohort, men with suspected prostate cancer who underwent biopsies were analysed. Data were obtained from medical records. Categorical variables were compared using Chi-square or Fisher’s exact test. Continuous variables were analysed with the Mann–Whitney <i>U</i> test in STATA version 18. <i>P</i> value ≤ 0.05 was considered significant.</p> Results <p>The 2023 cohort showed a significantly higher detection of clinically significant prostate cancer (Gleason ≥ 3 + 4) compared to the 2018 cohort (65.41% vs. 41%, <i>p</i> &lt; 0.01). Median Gleason scores increased from 6 to 7 (IQR 6–7 vs. 6–8, <i>p</i> &lt; 0.01). Hospital admissions decreased from 11.3% to 3% (<i>p</i> &lt; 0.01) in the 2023 cohort. Treatment and D’Amico’s risk groups showed no significant changes. Limitations include potential selection bias from only including biopsied patients and findings limited to two Danish hospitals, reducing generalizability.</p> Conclusion <p>Transitioning to targeted transperineal biopsies improved cancer detection and reduced complications. While the Gleason score increased, risk groups and treatment plans remained unchanged. These results support implementation in clinical practice, though further studies are needed to assess long-term outcomes and broader applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of a new diagnostic pathway for prostate cancer—from systematic transrectal to targeted MRI fusion transperineal biopsies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Sara Vejlgaard Kristensen,
  • Martin Wirenfeldt,
  • Katrine Thelle,
  • Else Brohm Kallestrup,
  • Mads Hvid Poulsen

摘要

Purpose

Advancements in prostate cancer diagnostics have changed the diagnostic pathway from traditional ultrasound-guided systematic transrectal biopsies to pre-biopsy prostate multiparametric MRI and targeted transperineal biopsies. This study aims to determine changes in prostate cancer detection rates, clinical outcomes, and treatment before (2018) and after (2023) implementing the new diagnostic pathway.

Methods

This retrospective study comprises two cohorts from two Danish hospitals—one from 2018 (n = 266) and one from 2023 (n = 304). In each cohort, men with suspected prostate cancer who underwent biopsies were analysed. Data were obtained from medical records. Categorical variables were compared using Chi-square or Fisher’s exact test. Continuous variables were analysed with the Mann–Whitney U test in STATA version 18. P value ≤ 0.05 was considered significant.

Results

The 2023 cohort showed a significantly higher detection of clinically significant prostate cancer (Gleason ≥ 3 + 4) compared to the 2018 cohort (65.41% vs. 41%, p < 0.01). Median Gleason scores increased from 6 to 7 (IQR 6–7 vs. 6–8, p < 0.01). Hospital admissions decreased from 11.3% to 3% (p < 0.01) in the 2023 cohort. Treatment and D’Amico’s risk groups showed no significant changes. Limitations include potential selection bias from only including biopsied patients and findings limited to two Danish hospitals, reducing generalizability.

Conclusion

Transitioning to targeted transperineal biopsies improved cancer detection and reduced complications. While the Gleason score increased, risk groups and treatment plans remained unchanged. These results support implementation in clinical practice, though further studies are needed to assess long-term outcomes and broader applicability.